Morphine and Hydromorphone Pharmacokinetics in Human Volunteers: Population-based Modelling of Interindividual and Opioid-related Variability

Overview

Journal Br J Anaesth

Publisher Elsevier

Specialty Anesthesiology

Date 2024 Nov 26

PMID 39592363

Authors

Konrad Meissner

Erik Olofsen

Albert Dahan

Evan D Kharasch

Affiliations

Soon will be listed here.

Abstract

Background: Morphine and hydromorphone have differing onsets, magnitudes, and durations of effects and side-effects. Differences between opioids in their interindividual variabilities in pharmacokinetics and pharmacodynamics might influence rational drug selection. Crossover drug studies can provide more informative interindividual variability data than parallel group studies. Using data from a crossover study of i.v. morphine and hydromorphone in healthy volunteers, we tested the hypothesis that morphine and hydromorphone differ in their interindividual pharmacokinetic variability.

Methods: Arterial opioid and metabolite concentrations from a randomised crossover study in 51 volunteers receiving a 2-h infusion of hydromorphone (0.05 or 0.1 mg kg i.v.) or morphine (total 0.1 or 0.2 mg kg i.v.) 1-2 weeks apart were evaluated with a three-compartmental model for parent opioid and incorporating glucuronides using population modelling (NONMEM). The primary outcome was interindividual variability in pharmacokinetics, based on the coefficient of variation (%CV) of individual model parameters, calculated as √[exp(ω)-1]×100 where ω is the interindividual variability.

Results: Data were analysed per drug and in a combined morphine-hydromorphone model. Both analyses indicate that interindividual variabilities for hydromorphone and morphine were comparable with %CV ranging from 9% to 31% for structural model parameters (combined analysis). Similarly, additive and relative residual errors had comparable variabilities, 20-40% and 72-87%, respectively, for morphine and hydromorphone (combined analysis).

Conclusions: Morphine and hydromorphone did not differ in a statistically significant or clinically meaningful manner in their interindividual pharmacokinetic variability. Interindividual pharmacokinetic variability does not appear a meaningful consideration in the choice between these two opioids.

References

Verscheijden L, Litjens C, Koenderink J, Mathijssen R, Verbeek M, de Wildt S . Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children. PLoS Comput Biol. 2021; 17(3):e1008786. PMC: 7963108. DOI: 10.1371/journal.pcbi.1008786. View

Chang A, Bijur P, Meyer R, Kenny M, Solorzano C, Gallagher E . Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial. Ann Emerg Med. 2006; 48(2):164-72. DOI: 10.1016/j.annemergmed.2006.03.005. View

Dahan A, van Dam C, Niesters M, van Velzen M, Fossler M, Demitrack M . Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine. Anesthesiology. 2020; 133(3):559-568. DOI: 10.1097/ALN.0000000000003441. View

de Vries M, Gravel J, Horn D, McLeod S, Varner C . Comparative efficacy of opioids for older adults presenting to the emergency department with acute pain: Systematic review. Can Fam Physician. 2019; 65(12):e538-e543. PMC: 6907377. View

Liu T, Ivaturi V, Gobburu J . Integrated Model to Describe Morphine Pharmacokinetics in Humans. J Clin Pharmacol. 2019; 59(8):1070-1077. DOI: 10.1002/jcph.1400. View

Meissner K, Dahan A, Olofsen E, Gopfert C, Blood J, Wieditz J . Morphine and Hydromorphone Effects, Side Effects, and Variability: A Crossover Study in Human Volunteers. Anesthesiology. 2023; 139(1):16-34. PMC: 10517626. DOI: 10.1097/ALN.0000000000004567. View

Osborne R, Joel S, Grebenik K, TREW D, Slevin M . The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 1993; 54(2):158-67. DOI: 10.1038/clpt.1993.127. View

Nielsen L, Sverrisdottir E, Stage T, Feddersen S, Brosen K, Christrup L . Lack of genetic association between OCT1, ABCB1, and UGT2B7 variants and morphine pharmacokinetics. Eur J Pharm Sci. 2017; 99:337-342. DOI: 10.1016/j.ejps.2016.12.039. View

de Hoogd S, Valitalo P, Dahan A, van Kralingen S, Coughtrie M, van Dongen E . Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide. Clin Pharmacokinet. 2017; 56(12):1577-1587. PMC: 5694499. DOI: 10.1007/s40262-017-0544-2. View

10.

Chang A, Bijur P, Baccelieri A, Gallagher E . Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial. Am J Geriatr Pharmacother. 2009; 7(1):1-10. DOI: 10.1016/j.amjopharm.2009.02.002. View

11.

Hill H, Coda B, Tanaka A, Schaffer R . Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects. Anesth Analg. 1991; 72(3):330-6. DOI: 10.1213/00000539-199103000-00009. View

12.

Yassen A, Passier P, Furuichi Y, Dahan A . Translational PK-PD modeling in pain. J Pharmacokinet Pharmacodyn. 2012; 40(3):401-18. DOI: 10.1007/s10928-012-9282-0. View

13.

Ing Lorenzini K, Daali Y, Dayer P, Desmeules J . Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview. Basic Clin Pharmacol Toxicol. 2011; 110(3):219-26. DOI: 10.1111/j.1742-7843.2011.00814.x. View

14.

Lotsch J, Stockmann A, Kobal G, Brune K, Waibel R, Schmidt N . Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther. 1996; 60(3):316-25. DOI: 10.1016/S0009-9236(96)90058-2. View

15.

Emoto C, Fukuda T, Johnson T, Neuhoff S, Sadhasivam S, Vinks A . Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter. CPT Pharmacometrics Syst Pharmacol. 2016; 6(2):110-119. PMC: 5321811. DOI: 10.1002/psp4.12144. View

16.

Parab P, Ritschel W, Coyle D, Gregg R, Denson D . Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects. Biopharm Drug Dispos. 1988; 9(2):187-99. DOI: 10.1002/bod.2510090207. View

17.

Murthy B, Pollack G, Brouwer K . Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol. 2002; 42(5):569-76. DOI: 10.1177/00912700222011508. View

18.

Belcher A, Khanna A, Leung S, Naylor A, Hutcherson M, Nguyen B . Long-Acting Patient-Controlled Opioids Are Not Associated With More Postoperative Hypoxemia Than Short-Acting Patient-Controlled Opioids After Noncardiac Surgery: A Cohort Analysis. Anesth Analg. 2016; 123(6):1471-1479. DOI: 10.1213/ANE.0000000000001534. View

19.

Lotsch J, Skarke C, Schmidt H, Liefhold J, Geisslinger G . Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. Clin Pharmacol Ther. 2002; 72(2):151-62. DOI: 10.1067/mcp.2002.126172. View

20.

Mazoit J, Butscher K, Samii K . Morphine in postoperative patients: pharmacokinetics and pharmacodynamics of metabolites. Anesth Analg. 2007; 105(1):70-8. DOI: 10.1213/01.ane.0000265557.73688.32. View